Literature DB >> 11746028

Saethre-Chotzen syndrome and hyper IgE syndrome in a patient with a novel 11 bp deletion of the TWIST gene.

A Boeck1, C Kosan, P Ciznar, J Kunz.   

Abstract

Molecular genetic studies in a seven-year-old boy and his mother demonstrated a novel 11 bp deletion in the TWIST gene (127del11), causing Saethre-Chotzen syndrome. The mother had rather mild signs of the Saethre-Chotzen syndrome; however, her son presented with marked acrocephalosyndactyly type 3, leading to craniotomy at three years. He also had recurrent infections and laboratory findings comparable with the hyper IgE syndrome, a rare primary immunodeficiency disorder. It is likely that the 11bp deletion caused the Saethre-Chotzen syndrome in the patient and his mother, and another, not yet identified genetic defect, seen in the patient but not in the mother, is responsible for the hyper IgE phenotype. A combination of these two congenital conditions has not been described to date. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746028     DOI: 10.1002/ajmg.10007

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

1.  Increased risk for developmental delay in Saethre-Chotzen syndrome is associated with TWIST deletions: an improved strategy for TWIST mutation screening.

Authors:  Juanliang Cai; Barbara K Goodman; Ankita S Patel; John B Mulliken; Lionel Van Maldergem; George E Hoganson; William A Paznekas; Ziva Ben-Neriah; Ruth Sheffer; Michael L Cunningham; Donna L Daentl; Ethylin Wang Jabs
Journal:  Hum Genet       Date:  2003-09-25       Impact factor: 4.132

2.  Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3.

Authors:  Cindy S Ma; Gary Y J Chew; Nicholas Simpson; Archana Priyadarshi; Melanie Wong; Bodo Grimbacher; David A Fulcher; Stuart G Tangye; Matthew C Cook
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

Review 3.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

Review 4.  An update on the hyper-IgE syndromes.

Authors:  Patrick F K Yong; Alexandra F Freeman; Karin R Engelhardt; Steven Holland; Jennifer M Puck; Bodo Grimbacher
Journal:  Arthritis Res Ther       Date:  2012-11-30       Impact factor: 5.156

5.  Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome.

Authors:  Vivien Béziat; Simon J Tavernier; Yin-Huai Chen; Cindy S Ma; Marie Materna; Arian Laurence; Jens Staal; Dominik Aschenbrenner; Lisa Roels; Lisa Worley; Kathleen Claes; Lisa Gartner; Lisa A Kohn; Marieke De Bruyne; Klaus Schmitz-Abe; Louis-Marie Charbonnier; Sevgi Keles; Justine Nammour; Natasha Vladikine; Majistor Raj Luxman Maglorius Renkilaraj; Yoann Seeleuthner; Mélanie Migaud; Jérémie Rosain; Mohamed Jeljeli; Bertrand Boisson; Eva Van Braeckel; Jill A Rosenfeld; Hongzheng Dai; Lindsay C Burrage; David R Murdock; Bart N Lambrecht; Véronique Avettand-Fenoel; Tiphanie P Vogel; Charles R Esther; Sule Haskologlu; Figen Dogu; Peter Ciznar; David Boutboul; Marie Ouachée-Chardin; Jean Amourette; Marie-Noëlle Lebras; Clément Gauvain; Colas Tcherakian; Aydan Ikinciogullari; Rudi Beyaert; Laurent Abel; Joshua D Milner; Bodo Grimbacher; Louis-Jean Couderc; Manish J Butte; Alexandra F Freeman; Émilie Catherinot; Claire Fieschi; Talal A Chatila; Stuart G Tangye; Holm H Uhlig; Filomeen Haerynck; Jean-Laurent Casanova; Anne Puel
Journal:  J Exp Med       Date:  2020-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.